Mainz, Germany, Sept. 15, 2020 (GLOBE NEWSWIRE) -- The German Federal Ministry of Education and Research (BMBF) COVID-19 initiative supports accelerated vaccine development, as well as upscaling of manufacturing capabilities in Germany Five out of eight milestones defined in the BMBF funding for the BNT162 vaccine program have already been achieved More than 28,000 participants have already been enrolled in the Phase 3 clinical trial currently being conducted in the United States, Brazil, Argentina and Europe MAINZ, GERMANY, September 15, 2020 - BioNTech SE (Nasdaq: BNTX, `BioNTech` or `the Company`) today announced that it will receive a grant of up to 375 million Euro from an initiative by...
|
